clinicaltrialsarena3h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
RSV vaccines are available for vulnerable adults and the ill. They just can’t afford them.
Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...
FierceBiotech5h
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
AARP18h
How Older Adults Can Survive the ‘Quad-emic’
Cases of flu, COVID and RSV (short for respiratory syncytial virus) tend to start climbing in the fall and peak in the winter months. Currently, emergency room visits for flu and RSV are high and ...
Indiatimes18h
Pfizer Share Price
Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has reported a Standalone Total ...